Rapport Therapeutics

Historical price data

Rapport Therapeutics is a clinical-stage biotech company founded in 2022 with a mission to develop precision medicines for complex neurological disorders by targeting receptor-associated proteins (RAPs). The company achieved a successful IPO in May 2024, raising significant capital to advance its lead clinical program, RAP-219, for treatment-resistant epilepsy and other indications. Its core strategy leverages a proprietary RAP platform to create neuroanatomically specific therapies, aiming to overcome the pervasive side effects that have plagued central nervous system drug development.

A proprietary platform for developing small molecule precision medicines that target Receptor-Associated Proteins (RAPs), which have restricted brain expression, to modulate primary neurotransmitter receptors only in specific neural circuits implicated in disease.

Rapport competes in crowded markets (epilepsy, pain) but is differentiated by its unique RAP-targeting approach for neuroanatomical precision. Its closest competitors are other precision neuroscience companies (e.g., Sage, Praxis), but Rapport's focus on auxiliary proteins like TARPγ8 provides a specialized niche and potential first-mover advantage.